Is Trident Texofab overvalued or undervalued?

As of 29 August 2025, the valuation grade for Trident Texofab has moved from very expensive to expensive. The company is currently considered overvalued based on its high valuation ratios. Key ratios include a PE ratio of 133.86, an EV to EBITDA of 76.80, and a PEG ratio of 6.36, which are significantly elevated compared to industry norms.
In comparison to peers, Trident Texofab's PE ratio stands out against Elitecon International, which is also very expensive at 752.77, and Lloyds Enterprises, which has a PE of 38.87. The disparity in these ratios indicates that Trident Texofab is not only expensive relative to its peers but also suggests a potential overvaluation given its lower ROCE of 4.27% and a relatively high EV to Sales ratio of 3.38. Notably, Trident Texofab has outperformed the Sensex with a remarkable 1-year stock return of 456.44%, which may further complicate its valuation narrative.